December 13, 2016
11 am to 12 pm EST

Sponsored by

Webinar Description:

The course will introduce covalent labeling mass spectrometry (CL-MS) to scientific professionals who are interested in learning about techniques to determine protein structure and mechanism of action in protein-ligand binding. CL-MS is recognized as an important option for determining antibody epitopes for intellectual property filings as well as understanding paratopes for protein engineering. Also, CL-MS can be used to establish biosimilarity to innovator drugs. CL-MS provides quantitative structural information on the interactions of solvent accessible side-chains that other protocols don’t provide and is ideal for studies on difficult complexes (including membrane proteins) where other techniques fail, while using picomoles of sample.

Learning Objectives:

• To gain an understanding of CL-MS vs. alternatives for protein structure assessment
• To understand chemistry of labeling of solvent accessible side chains in CL-MS
• To learn about applications of CL-MS to drug development problems in industry
• To learn about NeoProteomics’ turnkey service for mAb epitope and paratope characterization using CL-MS
• To understand how to integrate CL-MS with other data for integrated assessments of protein structure

Speaker:

Dr. Mark R. Chance

Founder, CSO

NeoProteomics, Inc.

Dr. Mark R. Chance is a national leader in proteomics and bioinformatics research and responsible for determining the scientific vision and direction of NeoProteomics as the company founder and Chief Scientific Officer. Dr. Chance is also currently Vice Dean for Research, Director of the Center for Proteomics and Bioinformatics, and Professor in the Department of Nutrition and the Department of Genetics and Genome Sciences at the Case Western Reserve University School of Medicine. He is an internationally recognized expert in proteomics and structural biology with over 270 publications that have been cited over 10,000 times who has built multiple internationally recognized science and training programs over a 25-year career in academia. Currently, as Director of the Center for Proteomics and Bioinformatics at Case Western Reserve University he is involved in leading and supporting a wide range of research programs using technologies ranging from next generation sequencing to mass spectrometry to crystallography and in fields from cancer to infectious disease to vision research. He has been a leader in clinical and translational research within the Center for Translational Science Collaborative and the Case Comprehensive Cancer Center.